Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Summary

This phase I/II trial studies the side effects and the best dose of MLN8237 when given together with erlotinib hydrochloride and to see how well it works in treating patients with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC). MLN8237 and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2011-10-20

Primary completion

2017-02-07

Completion

2018-04-10

Outcome

Outcome not reported

Stopped: “Phase I portion completed. Phase II will open pending amendment approval.”

Drugs

Indications